newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

  • Immix Biopharma closed its underwritten registered offering of 19,117,646 common shares at $5.10 per share & pre-funded warrants for 490,196 shares at $5.09 per warrant.
  • Net proceeds from the offering totaled approximately $93.7 million after deducting underwriting discounts, commissions & other expenses.
  • The financing included leading U.S. biotechnology institutional investors & mutual funds.
  • Morgan Stanley served as the sole book-running manager, while Citizens Capital Markets & Mizuho acted as co-managers.
  • The securities were sold pursuant to a shelf registration statement on Form S-3 filed with the SEC on January 3, 2023.
  • Immix Bio is a global leader in relapsed/refractory AL Amyloidosis with lead candidate NXC-201, a CAR-T therapy receiving RMAT & Orphan Drug Designations.